Serum endocan (ESM-1) as diagnostic and prognostic biomarker in Multisystem inflammatory syndrome in children (MIS-C)

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine Pub Date : 2024-11-01 DOI:10.1016/j.cyto.2024.156797

Alessandro Cannavo , Monica Gelzo , Caterina Vinciguerra , Graziamaria Corbi , Marco Maglione , Vincenzo Tipo , Antonietta Giannattasio , Giuseppe Castaldo

{"title":"Serum endocan (ESM-1) as diagnostic and prognostic biomarker in Multisystem inflammatory syndrome in children (MIS-C)","authors":"Alessandro Cannavo , Monica Gelzo , Caterina Vinciguerra , Graziamaria Corbi , Marco Maglione , Vincenzo Tipo , Antonietta Giannattasio , Giuseppe Castaldo","doi":"10.1016/j.cyto.2024.156797","DOIUrl":null,"url":null,"abstract":"<div><div>Endothelial-cell-specific molecule-1 (ESM-1) also called endocan is a well-known biomarker for detecting inflammation, endothelial dysfunction (ED), and cardiovascular (CV) risk in COVID-19 patients. Upon SARS-CoV-2 infection, a small percentage of children develop Multisystem Inflammatory Syndrome in children (MIS-C). Whether endocan can be used as a biomarker of MIS-C is unknown. In this study, we assessed ESM-1 levels in MIS-C (n = 19) and healthy controls (HC; n = 17). We observed a significant increase in serum ESM-1 levels in MIS-C vs HC (p = 0.0074). In addition, ROC curve analysis demonstrated that this factor has a reasonable discriminatory power between MIS-C patients and HC (AUC of 0.7585). Notably, after one week of hospitalization and care, ESM-1 levels decreased, and this reduction was observed also for other inflammatory and pro-thrombotic markers like C-reactive protein, procalcitonin, fibrinogen, D-dimer, and ferritin, suggesting a general recovery trend in MIS-C patients. In fact, we observed that serum ESM-1 levels positively correlated with procalcitonin (PCT) (r = 0.468; p = 0.043). Finally, logistic regression analysis demonstrated an association between endocan levels and cardiac complications like myocarditis. Therefore, this study suggests that ESM-1 is a valuable diagnostic and prognostic biomarker in patients with MIS-C that may help identify those MIS-C patients at higher risk for cardiovascular complications and guide treatment strategies.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"184 ","pages":"Article 156797"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624003016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Endothelial-cell-specific molecule-1 (ESM-1) also called endocan is a well-known biomarker for detecting inflammation, endothelial dysfunction (ED), and cardiovascular (CV) risk in COVID-19 patients. Upon SARS-CoV-2 infection, a small percentage of children develop Multisystem Inflammatory Syndrome in children (MIS-C). Whether endocan can be used as a biomarker of MIS-C is unknown. In this study, we assessed ESM-1 levels in MIS-C (n = 19) and healthy controls (HC; n = 17). We observed a significant increase in serum ESM-1 levels in MIS-C vs HC (p = 0.0074). In addition, ROC curve analysis demonstrated that this factor has a reasonable discriminatory power between MIS-C patients and HC (AUC of 0.7585). Notably, after one week of hospitalization and care, ESM-1 levels decreased, and this reduction was observed also for other inflammatory and pro-thrombotic markers like C-reactive protein, procalcitonin, fibrinogen, D-dimer, and ferritin, suggesting a general recovery trend in MIS-C patients. In fact, we observed that serum ESM-1 levels positively correlated with procalcitonin (PCT) (r = 0.468; p = 0.043). Finally, logistic regression analysis demonstrated an association between endocan levels and cardiac complications like myocarditis. Therefore, this study suggests that ESM-1 is a valuable diagnostic and prognostic biomarker in patients with MIS-C that may help identify those MIS-C patients at higher risk for cardiovascular complications and guide treatment strategies.

Abstract Image

查看原文本刊更多论文

血清内切酶（ESM-1）作为儿童多系统炎症综合征（MIS-C）的诊断和预后生物标志物。

内皮细胞特异性分子-1（ESM-1）又称内皮素，是检测 COVID-19 患者炎症、内皮功能障碍（ED）和心血管（CV）风险的著名生物标志物。感染 SARS-CoV-2 后，一小部分儿童会出现儿童多系统炎症综合征（MIS-C）。内切酶能否作为儿童多系统炎症综合征（MIS-C）的生物标志物尚不清楚。在这项研究中，我们评估了 MIS-C（19 人）和健康对照组（17 人）的 ESM-1 水平。我们观察到，与健康对照组相比，MIS-C 患者血清中的 ESM-1 水平明显升高（p = 0.0074）。此外，ROC 曲线分析表明，该因子在 MIS-C 患者和 HC 之间具有合理的区分能力（AUC 为 0.7585）。值得注意的是，经过一周的住院和护理后，ESM-1 水平有所下降，而且其他炎症和促血栓形成标志物，如 C 反应蛋白、降钙素原、纤维蛋白原、D-二聚体和铁蛋白的水平也有所下降，这表明 MIS-C 患者的血清 ESM-1 水平呈总体恢复趋势。事实上，我们观察到血清 ESM-1 水平与降钙素原 (PCT) 呈正相关（r = 0.468; p = 0.043）。最后，逻辑回归分析表明，内切酶水平与心肌炎等心脏并发症存在关联。因此，这项研究表明，ESM-1 是 MIS-C 患者的一种有价值的诊断和预后生物标志物，可帮助识别心血管并发症风险较高的 MIS-C 患者并指导治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.